New combo targets stubborn lung cancer cells that survive first-line therapy
NCT ID NCT07375316
First seen Jan 30, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer DNA (ctDNA) remains detectable in the blood after a few weeks on the drug osimertinib alone. Those patients tend to do worse, so researchers want to see if adding a second drug (sacituzumab tirumotecan) can improve outcomes. About 120 adults will receive the combination, and the main goal is to measure how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences
RECRUITINGMeizhou, Guangdong, 514031, China
Contact
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact
-
The First Affiliated Hospital of Shantou University Medical College
RECRUITINGShantou, Guangdong, 515041, China
Conditions
Explore the condition pages connected to this study.